IL-15 Responsive Luciferase Reporter Cell Line
This recombinant Jurkat cell line is a biologically relevant system to measure activation of the IL-15 cytokine receptor by IL-15. The cells were engineered for constitutive expression of human CD122 (IL-15Rβ; IL-2Rβ; NM_000878.4), and conditional expression of firefly luciferase driven by STAT5 response elements located upstream of the minimal TATA promoter. Expression of CD122 allows formation of a functional IL-15 receptor at the surface of Jurkat cells, which naturally express high levels of CD132 (also known as IL-15 receptor subunit γc). Activation of the STAT5 signaling pathway in response to IL-15 or IL-15 analogs can be monitored by measuring luciferase activity.
Interested in screening and profiling inhibitors, blocking antibodies, or activators of IL-15 signaling without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2A | BPS Bioscience #60190 |
Materials Required for Cellular Assay
Name | Ordering Information |
Recombinant Human IL-15 (rhIL-15) | Peprotech #200-15 |
Assay Medium: Thaw Medium 2 | BPS Bioscience #60184 |
96-well tissue culture treated, white, clear-bottom assay plate | Corning #3610 |
ONE-Step™ luciferase assay system | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
IL-15 is a proinflammatory cytokine mainly produced in dendric cells (DC) and monocytes. It remains associated with IL-15Rα on the surface of DC and monocytes, and binds to the CD122/CD132 heterodimeric receptor present at the surface of various target immune cells, including CD8+ memory T cells, resulting in their proliferation and differentiation. Although there is no indication that unassociated IL-15 exists in vivo, soluble recombinant IL-15 and its analogs have been examined for their therapeutic potential.